Publication

Modelling in miniature: Using Drosophila melanogaster to study human neurodegeneration

Lambrechts, R., Faber, A. & Sibon, O., 1-Dec-2017, In : Drug Discovery Today: Disease Models. 25-26, p. 3-10 8 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Lambrechts, R., Faber, A., & Sibon, O. (2017). Modelling in miniature: Using Drosophila melanogaster to study human neurodegeneration. Drug Discovery Today: Disease Models, 25-26, 3-10. https://doi.org/10.1016/j.ddmod.2018.09.004

Author

Lambrechts, Roald ; Faber, Anita ; Sibon, Ody. / Modelling in miniature : Using Drosophila melanogaster to study human neurodegeneration. In: Drug Discovery Today: Disease Models. 2017 ; Vol. 25-26. pp. 3-10.

Harvard

Lambrechts, R, Faber, A & Sibon, O 2017, 'Modelling in miniature: Using Drosophila melanogaster to study human neurodegeneration', Drug Discovery Today: Disease Models, vol. 25-26, pp. 3-10. https://doi.org/10.1016/j.ddmod.2018.09.004

Standard

Modelling in miniature : Using Drosophila melanogaster to study human neurodegeneration. / Lambrechts, Roald; Faber, Anita; Sibon, Ody.

In: Drug Discovery Today: Disease Models, Vol. 25-26, 01.12.2017, p. 3-10.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Lambrechts R, Faber A, Sibon O. Modelling in miniature: Using Drosophila melanogaster to study human neurodegeneration. Drug Discovery Today: Disease Models. 2017 Dec 1;25-26:3-10. https://doi.org/10.1016/j.ddmod.2018.09.004


BibTeX

@article{4cb19c06ba4c4221945cc7dc2f81f7d8,
title = "Modelling in miniature: Using Drosophila melanogaster to study human neurodegeneration",
abstract = "Despite great advances in clinical diagnostics, genetics and molecular biology, neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD) and Huntington's disease (HD) still pose great challenges, both in terms of understanding their pathophysiology as well as their treatment. Organisms able to adequately model the intricacies of the disease mechanism and respose to potential treatment, whilst not compromising on ease of handling, studying and manipulating in order to study them, represent the holy grail of translational biology and medicine. Here, we review the suitability of the fruit fly, Drosophila melanogaster, as a model organism in the field of neurodegeneration. We briefly summarize the history of scientific research concerning this organism, review the molecular, genetic and pharmacological toolbox available and we discuss the ways this toolbox has been applied to research in neurodegeneration. Finally, by reviewing some findings in the fruit fly which were subsequently translated to and validated in other organisms on their way to the clinic, the power and robustness of Drosophila melanogaster is highlighted.",
author = "Roald Lambrechts and Anita Faber and Ody Sibon",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.ddmod.2018.09.004",
language = "English",
volume = "25-26",
pages = "3--10",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",

}

RIS

TY - JOUR

T1 - Modelling in miniature

T2 - Using Drosophila melanogaster to study human neurodegeneration

AU - Lambrechts, Roald

AU - Faber, Anita

AU - Sibon, Ody

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Despite great advances in clinical diagnostics, genetics and molecular biology, neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD) and Huntington's disease (HD) still pose great challenges, both in terms of understanding their pathophysiology as well as their treatment. Organisms able to adequately model the intricacies of the disease mechanism and respose to potential treatment, whilst not compromising on ease of handling, studying and manipulating in order to study them, represent the holy grail of translational biology and medicine. Here, we review the suitability of the fruit fly, Drosophila melanogaster, as a model organism in the field of neurodegeneration. We briefly summarize the history of scientific research concerning this organism, review the molecular, genetic and pharmacological toolbox available and we discuss the ways this toolbox has been applied to research in neurodegeneration. Finally, by reviewing some findings in the fruit fly which were subsequently translated to and validated in other organisms on their way to the clinic, the power and robustness of Drosophila melanogaster is highlighted.

AB - Despite great advances in clinical diagnostics, genetics and molecular biology, neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD) and Huntington's disease (HD) still pose great challenges, both in terms of understanding their pathophysiology as well as their treatment. Organisms able to adequately model the intricacies of the disease mechanism and respose to potential treatment, whilst not compromising on ease of handling, studying and manipulating in order to study them, represent the holy grail of translational biology and medicine. Here, we review the suitability of the fruit fly, Drosophila melanogaster, as a model organism in the field of neurodegeneration. We briefly summarize the history of scientific research concerning this organism, review the molecular, genetic and pharmacological toolbox available and we discuss the ways this toolbox has been applied to research in neurodegeneration. Finally, by reviewing some findings in the fruit fly which were subsequently translated to and validated in other organisms on their way to the clinic, the power and robustness of Drosophila melanogaster is highlighted.

U2 - 10.1016/j.ddmod.2018.09.004

DO - 10.1016/j.ddmod.2018.09.004

M3 - Review article

AN - SCOPUS:85054713486

VL - 25-26

SP - 3

EP - 10

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

ER -

ID: 101649663